BNP and congestive heart failure

Progress in Cardiovascular Diseases

Volumn 44, Issue 4, 2002, Pages 293-321

  Cowie, Martin R ^a,b   Mendez, Gustavo F ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ANALYTIC METHOD; ARTICLE; CELL SECRETION; CONGESTIVE HEART FAILURE; DIAGNOSTIC VALUE; DRUG MECHANISM; DYSPNEA; FLUID RETENTION; FUNCTIONAL ASSESSMENT; HEART DISEASE; HEART FAILURE; HEART FUNCTION TEST; HEART VENTRICLE WALL; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; PATIENT MONITORING; PEPTIDE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; SMOOTH MUSCLE FIBER;

EID: 0036231806     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.24599     Document Type: Article

References (231)

1. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides
2. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease
3. Renal natriuretic peptide (urodilatin?) and atriopeptin: Evolving concepts
4. Purification and complete amino acid sequence of alpha-human atrial natriuretic peptide (alpha-hANP)
5. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
6. Natriuretic peptides
7. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man
8. Atrial and brain natriuretic peptides: A dual natriuretic peptide system potentially involved in circulatory homeostasis
9. A new natriuretic peptide in porcine brain
10. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
11. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide
12. Expression of brain natriuretic peptide gene in human heart: Production in the ventricle
13. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide
14. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain
15. Distribution and characterization of immunoreactive porcine C-type natriuretic peptide
16. The role of C-type natriuretic peptide in cardiovascular medicine
17. Isolation and structural analysis of "urodilatin" a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
18. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)
19. Presence of dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure
20. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes
21. Natriuretic peptides - Relevance in cardiovascular disease
22. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes
23. Natriuretic peptide system in human heart failure
24. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy
25. Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy
26. The role of the circulation in processing pro-Brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32
27. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans
28. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases
29. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans
30. Mechanical and neuroendocrine regulation of the endocrine heart
31. Involvement of transcriptional and posttranscriptional mechanisms in cardiac overload-induced increase of B-type natriuretic peptide gene expression
32. Cosecretion of peptides derived from gamma-human atrial natriuretic polypeptide in normal volunteers and patients with essential hypertension and adrenal disorders
33. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man
34. Atrial and brain natriuretic peptides in cardiovascular diseases
35. Dietary sodium loading increases plasma brain natriuretic peptide levels in man
36. Brain and atrial natriuretic peptides: A dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypertension
37. Plasma brain natriuretic peptide in athletes
38. Cardiac peptides differ in their response to exercise: Implications for patients with heart failure in clinical practice
39. Relationship between natriuretic peptides and hemodynamics in patients with heart failure at rest and after ergometric exercise
40. Effects of exercise on plasma levels of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction
41. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty
42. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty
43. Transient myocardial ischemia stimulates atrial natriuretic factor release
44. Atrial natriuretic peptide during myocardial ischemia induced by percutaneous transluminal coronary angioplasty
45. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina
46. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload
47. Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes
48. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro
49. Expression and distribution of brain natriuretic peptide in human right atria
50. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats
51. Regulation of gene expression in the endocrine heart
52. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: Marked and rapid increase after birth
53. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
54. Receptors of atrial natriuretic factor
55. The natriuretic peptides and their receptors
56. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors
57. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide
58. Atrial natriuretic peptide clearance receptor: Complete sequence and functional expression of cDNA clones
59. Natriuretic peptide C-receptor: More than a clearance receptor
60. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases
61. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor
62. Molecular biology of the natriuretic peptides and their receptors
63. Atrial natriuretic peptide-C receptor and membrane signalling in hypertension
64. Atrial natriuretic peptide clearance receptor participates in modulating endothelial permeability
65. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure
66. Brain natriuretic peptide administered to man: Actions and metabolism
67. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man
68. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans
69. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney
70. Effect of porcine brain natriuretic peptide (pBNP) on human adrenocortical steroidogenesis
71. Brain natriuretic peptide receptors in the rat peripheral sympathetic ganglia
72. Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits
73. Cardiac fibrosis in mice lacking brain natriuretic peptide
74. Vascular actions of brain natriuretic peptide: Modulation by atherosclerosis and neutral endopeptidase inhibition
75. Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells
76. Suppression of hyperventilation-induced attacks with infusion of atrial natriuretic peptide in patients with variant angina pectoris
77. Suppression of hyperventilation-induced attacks with infusion of B-type (brain) natriuretic peptide in patients with variant angina
78. Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans
79. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale: Hemodynamic and endocrine effects
80. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium
81. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man
82. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog
83. Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease
84. Atrial natriuretic peptide in humans: Production and clearance by various tissues
85. Amino-terminal proBNP in ovine plasma: Evidence for enhanced secretion in response to cardiac overload
86. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study
87. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure
88. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines
89. Measurement and significance of circulating natriuretic peptides in cardiovascular disease
90. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods
91. Analytical agreement and clinical correlates of plasma brain natriuretic peptide measured by three immunoassays in patients with heart failure
92. Cardiac peptide stability, aprotonin and room temperature: Importance for assessing cardiac function in clinical practice
93. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro
94. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
95. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: Implications for assessment of left ventricular dysfunction
96. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit
97. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea
98. Evaluation of the analytical performance of RIA methods for measurement of ANP
99. An immunoradiometric assay for brain natriuretic peptide in human plasma
100. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with differing degrees of heart failure
101. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology
102. B-type Natriuretic Peptide (BNP) - Validation of an immediate response assay
103. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction
104. The aminoterminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma
105. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: Development of a test for left ventricular dysfunction
106. Cardiac diseases
107. Brain natriuretic peptide in an elderly population
108. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
109. Validity of clinical diagnosis of heart failure in primary health care
110. Incidence and aetiology of heart failure: A population-based study
111. Coronary artery disease as the cause of incident heart failure in the population
112. Guidelines for the diagnosis of heart failure
113. ACC/AHA guidelines for the clinical application of echocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography)
114. Increased human brain natriuretic peptide in congestive heart failure
115. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
116. Plasma brain natriuretic peptide in assessment of acute dyspnoea
117. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea
118. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting
119. Guidelines for the diagnosis and treatment of chronic heart failure
120. The epidemiology of heart failure
121. Annotated references in epidemiology
122. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
123. Plasma N-terminal proBNP and cardiotrophin-1 are elevated in aortic stenosis
124. Plasma levels of brain natriuretic peptide and atrial natriuretic peptides elevate in proportion to left ventricular endsystolic wall stress in patients with aortic stenosis
125. Brain natriuretic peptide concentrations in patients with aortic stenosis
126. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction
127. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation
128. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-ProBNP): A new marker of cardiac impairment
129. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure
130. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
131. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
132. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
133. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohormonal plasma concentrations
134. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction
135. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy
136. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern
137. Heart failure with normal systolic function: A common disorder in older people
138. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective
139. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty
140. Relationships between plasma level of brain natriuretic peptide and myocardial infarct size
141. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction
142. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction
143. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction
144. Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical, echocardiographic, and neurohormonal methods
145. Plasma brain natriuretic peptide as an indicator of left ventricular systolic dysfunction and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
146. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care
147. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction
148. American College of Cardiology/American Heart Association guidelines for the management of patients with acute myocardial infarction: 1999 Update: A report of the ACC/AHA Task Force on Practice Guidelines/ Committee on Management of Acute Myocardial Infarction
149. Acute myocardial infarction: Pre-hospital and in-hospital management
150. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?
151. Screening by brain natriuretic peptide is cost effective to detect left ventricular systolic dysfunction in subjects at risk in general practice
152. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels
153. Biochemical detection of left-ventricular systolic dysfunction
154. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study
155. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community
156. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population
157. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program
158. Risk factors for doxorubicin-induced congestive heart failure
159. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects
160. Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity
161. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
162. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: Correlations between plasma neurohormones and right ventricular dysfunction
163. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia
164. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
165. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
166. Prognostic value of neurohormonal activation in patients with acute myocardial infarction: Effect of captopril
167. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
168. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
169. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction
170. N-terminal pro-BNP predicts prognosis in patients presenting with heart failure for the first time better than does N-terminal pro-ANP or BNP
171. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study
172. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
173. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction
174. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
175. Brain natriuretic peptide predicts mortality in the elderly
176. Atrial natriuretic peptides predict mortality in the elderly
177. Atrial natriuretic peptide levels in the prediction of congestive heart failure in frail elderly
178. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension
179. Consensus recommendations for the management of chronic heart failure
180. The treatment of heart failure
181. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of hemodynamic and neuroendocrine effects of tailored versus empirical therapy
182. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
183. Neurohormonal prediction of benefit from carvedilol in ischemic left ventricular dysfunction
184. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit with carvedilol in chronic ischemic left ventricular dysfunction
185. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide
186. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
187. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial
188. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
189. Nesiritide for the treatment of decompensated heart failure
190. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial
191. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
192. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure
193. Influence of candoxatril on plasma brain natriuretic peptide in heart failure
194. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
195. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure
196. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure
197. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure
198. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
199. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure
200. Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors
201. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin converting enzyme and neutral endopeptidase
202. Vasopeptidase inhibition: A new concept in blood pressure management
203. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
204. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
205. Effects of omapatrilat on systemic arterial function in patients with chronic heart failure
206. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease
207. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale
208. Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory disease
209. Brain natriuretic peptide as a cardiac hormone in essential hypertension
210. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor
211. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension
212. Raised plasma concentrations of brain natriuretic peptide in pulmonary arterial hypertension
213. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy
214. Atrial natriuretic peptide: Synthesis, release, and metabolism
215. Plasma levels of atrial natriuretic hormone in Cushing's syndrome
216. Plasma atrial natriuretic peptide concentration in patients with primary aldosteronism
217. Plasma levels of atrial natriuretic peptide in primary aldosteronism and essential hypertension
218. Raised plasma levels of atrial natriuretic peptides in Addison's disease
219. Atrial natriuretic peptide in diabetic nephropathy
220. Atrial natriuretic factor and digoxin-like immunoreactive factor in diabetic patients: Their interrelation and the influence of the autonomic nervous system
221. Determinants of intra-individual variation in kidney function in normoalbuminuric insulin-dependent diabetic patients: Importance of atrial natriuretic peptide and glycaemic control
222. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria
223. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention
224. Plasma human brain natriuretic peptide in chronic renal failure
225. Plasma levels of atriaJ natriuretic peptide in patients with chronic renal failure
226. Ectopic production and processing of atrial natriuretic peptide in a small call lung carcinoma cell line and tumor from a patient with hyponatremia
227. Paraneoplastic syndromes associated with small cell lung cancer
228. Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage
229. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage: Clinical and TCD correlations
230. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction